中国P站

Abstract

Population pharmacokinetic (PopPK) modeling is essential in drug development and clinical practice for understanding drug exposure and response variability. Advancements include integrating omics data and real-world evidence. The synergy of PopPK with physiologically based pharmacokinetic (PBPK) modeling enhances predictive capabilities, particularly for drug-drug interactions and special populations. Bayesian approaches improve analyses with sparse data, while genetic polymorphism impacts are crucial for personalized therapy. Real-world data offers generalizability, and PopPK is vital for pediatric dosing and managing drug-drug interactions. Advanced statistical methods address sparse sampling, and emerging machine learning integration promises further predictive improvements. PopPK is a cornerstone of model-informed drug development (MIDD), guiding dose selection and regulatory processes for safer, more effective medicines.